Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | KRAS | P01116 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912011 | 1.00 | TLR8 (0.38) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL29081534 | 1.00 | TLR8 (0.38) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL29081533 | 1.00 | TLR8 (0.38) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL29081246 | 0.96 | TLR8 (0.37) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL29081248 | 0.96 | TLR8 (0.37) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL29081922 | 0.96 | TLR8 (0.37) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL25911939 | 0.96 | TLR8 (0.40) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL25333593 | 0.93 | IRAK4 (0.34) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL25333589 | 0.93 | IRAK4 (0.34) | TLR8GPR119IRAK4KDM5ACHEK2 | |
| SCHEMBL25430304 | 0.93 | IRAK4 (0.34) | TLR8GPR119IRAK4KDM5ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | TLR8 4499/4885GPR119 1037/4885IRAK4 4158/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TLR8 2353/4885GPR119 216/4885IRAK4 3901/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | TLR8 2684/4885GPR119 630/4885IRAK4 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.